NCT05753332 is a clinical trial in Exposure to Polluted Air, sponsored by Northern Jiangsu People's Hospital.

Who is sponsoring NCT05753332?

NCT05753332 is sponsored by Northern Jiangsu People's Hospital.

What condition does NCT05753332 study?

NCT05753332 studies Exposure to Polluted Air.

Is NCT05753332 still recruiting?

NCT05753332 is currently status unknown. Last updated 3 March 2023.

Last reviewed 2023-03-03 · How we verify

NCT05753332

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between PM2.5 and Ferroptosis

Status unknown Last updated 3 March 2023

What this trial tests

trial in Exposure to Polluted Air in 60 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
25 February 2023

1 March 2023

Quick facts

Lead sponsor	Northern Jiangsu People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 December 2022
Primary completion	25 February 2023
Estimated completion	1 March 2023
Sites	1 location across China

Conditions studied

Exposure to Polluted Air — all drugs for Exposure to Polluted Air →

Sponsor

Northern Jiangsu People's Hospital

Who can join

18 and older, any sex, with Exposure to Polluted Air. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This cohort study aims to discover the possible effects of PM2.5 exposures on the Nrf2- dependent ferroptosis pathway. This observational cohort's main question is whether PM2.5 exposures will affect the Nrf2- dependent ferroptosis pathway. Participants will be divided into two groups: the control group and the air pollution to detect the biomarkers of the Nrf2- dependent ferroptosis pathway.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

In defence of ferroptosis.
Alves F, Lane D, Nguyen TPM, Bush AI, et al · · 2025 · cited 75× · PMID 39746918 · DOI 10.1038/s41392-024-02088-5

Verify or expand the search:

Other Northern Jiangsu People's Hospital trials

Trials by the same sponsor.

NCT07490405 — Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism · NA · not yet recruiting
NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05753332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northern Jiangsu People's Hospital
Last refreshed: 3 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05753332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing